SCHEMBL7542234

SCHEMBL7542234

CC(=O)NS(=O)(=O)c1ccc(C=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.62
TDP1 Q9NUW8 2/20 0.62
DHFR P00374 1/20 0.62
TSHR P16473 1/20 0.62
AKR1C2 P52895 1/20 0.57
AKR1C1 Q04828 1/20 0.57
PKM P14618 2/20 0.53
POLB P06746 2/20 0.53
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50
MMP9 P14780 1/20 0.50
MMP13 P45452 1/20 0.50
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12264953 0.84 TDP1 (0.61) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL5931251 0.79 SMN1; SMN2 (0.69) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL7541831 0.79 SMN1; SMN2 (0.69) SMN1; SMN2TDP1DHFRTSHRAKR1C2
Sulfacetamide SCHEMBL28376462 0.77 SMN1; SMN2 (0.83) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL22084439 0.77 MMP1 (0.44) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL7402304 0.77 TSHR (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL8777213 0.77 SMN1; SMN2 (0.67) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL16296754 0.77 SMN1; SMN2 (0.67) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL1684446 0.77 DHFR (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
Sulfacetamide SCHEMBL40863 0.77 SMN1; SMN2 (1.00) SMN1; SMN2TDP1DHFRTSHRAKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013149996-A9 SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS ALMIRALL, S.A. (ES) 2014-02-20 WO disclosed
WO-2013149996-A1 SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS ALMIRALL, S.A. (ES) 2013-10-10 WO disclosed
US-20020094993-A1 Compositions for repelling crawling insects S.C. JOHNSON & SON, INC. 2002-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094993-A1 Compositions for repelling crawling insects ACHE, DDT, GAP43 SMN1; SMN2 2971/4885TDP1 3063/4885DHFR 4154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.